Clinical Trials Logo

Recurrent Malignant Glioma clinical trials

View clinical trials related to Recurrent Malignant Glioma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01904123 Completed - Metastatic Melanoma Clinical Trials

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

Start date: July 13, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system.